MabVax Therapeutics Board Of Directors Authorizes The Company To Explore Strategic Alternatives Post author:Sam Post published:July 23, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like San Diego's Halozyme Lands Potential $680M R&D Deal With Alexion December 6, 2017 BioTime Expands OpRegen Clinical Trial In Dry-AMD With Opening Of First U.S. Sites March 12, 2017 Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia May 18, 2017
Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia May 18, 2017